NYSE$SRNE
Sorrento Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported continuous sales growth in ZTlido.
Scilex Holding Company reported preliminary gross sales of approximately $18.4 million for ZTlido in 1Q2022, representing a 26% growth compared to 1Q2021.
- Preliminary gross sales for ZTlido in 1Q2022 were approximately $18.4 million.
- ZTlido sales in 1Q2022 grew by 26% compared to 1Q2021.
- March 2022 ZTlido sales were $8.1 million, a 53% increase year-over-year.
- Scilex is focused on expanding payor coverage for ZTlido as a first-line therapy for neuropathic pain.
Headline financials
Revenue & EPS history
Sorrento · Revenue · Quarterly
$18.4M
Revenue by segment
Sorrento · $18.4M total across 1 segment · Q1 2022
- ZTlido$18.4M+26.0%100.0%
Forward guidance
Scilex Holding Company and Vickers Vantage Corp. I entered into a definitive business combination agreement on March 17, 2022, with the closing expected by the third quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.3%
Avg return
Earnings day
+3.1%
Avg return
5 days after
+6.9%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+41.2%
Q2 2020
Best reaction
-15.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2023 | +29.2% | +7.3% | +207.9% | |
| Q2 2023 | +11.6% | -13.9% | +16.7% | |
| Q1 2023 | -4.3% | +2.7% | -15.1% | |
| Q4 2022 | +13.8% | +25.6% | +5.6% | |
| Q3 2022 | -2.8% | +26.2% | -25.5% | |
| Q2 2022 | -4.2% | -29.3% | -21.3% | |
| Q1 2022 | -6.9% | -15.1% | -25.4% | |
| Q4 2021 | -11.1% | +6.7% | -12.4% | |
| Q3 2021 | -4.8% | -7.2% | -28.3% | |
| Q2 2021 | +2.7% | +4.7% | +2.9% | |
| Q1 2021 | +0.1% | +3.4% | +2.9% | |
| Q4 2020 | +0.0% | -14.4% | -25.4% | |
| Q3 2020 | -15.6% | -7.6% | +17.6% | |
| Q2 2020 | +41.2% | +47.6% | -27.7% | |
| Q1 2020 | -6.5% | +34.1% | +22.7% | |
| Q4 2019 | -3.2% | +0.0% | -8.6% | |
| Q3 2019 | -6.0% | -8.4% | +149.7% | |
| Q2 2019 | -6.8% | -6.8% | -2.7% | |
| Q1 2019 | -10.5% | -9.5% | -23.2% | |
| Q4 2017 | +13.2% | +43.6% | +70.8% | |
| Q4 2018 | +13.2% | +43.6% | +70.8% | |
| Q3 2018 | -12.8% | -17.8% | -25.0% | |
| Q2 2018 | +0.9% | -4.7% | -7.5% | |
| Q1 2018 | -7.8% | +4.9% | +19.4% | |
| Q3 2017 | +0.0% | -11.5% | -13.5% | |
| Q2 2017 | -10.3% | -9.0% | -10.3% | |
| Q1 2017 | -10.0% | -16.3% | -51.2% | |
| Q4 2016 | +1.2% | -1.2% | -56.6% | |
| Q3 2016 | +7.3% | +19.1% | -1.8% | |
| Q2 2016 | +0.1% | -4.5% | +1.0% | |
| Q1 2016 | +4.2% | — | — | |
| Q4 2015 | -13.6% | — | — | |
| Q3 2015 | -9.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro